Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia Academic Article uri icon

Overview

MeSH Major

  • Bacterial Toxins
  • Exotoxins
  • Immunotherapy
  • Leukemia, Hairy Cell
  • Sialic Acid Binding Ig-like Lectin 2

abstract

  • Moxetumomab pasudotox at doses up to 50 μg/kg QOD ×3 has activity in relapsed/refractory HCL and has a safety profile that supports further clinical development for treatment of this disease.

publication date

  • May 20, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3383181

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.38.1756

PubMed ID

  • 22355053

Additional Document Info

start page

  • 1822

end page

  • 8

volume

  • 30

number

  • 15